Pulmatrix Expects Key Results of Phase 1/1b Trial of Lung Fungus Treatment by Mid-2018
Key results of a Phase 1/1b clinical trial of Pulmatrix’s lead treatment for fungal infections in asthma and cystic fibrosis (CF) are expected by mid-2018, the company reports. The trial, which started in February, is focusing on pulmazole’s safety and patients’ ability to tolerate it. Pulmatrix expects the results to…